Evidence map›Paper›PMID 39508966›Full record

ArticleMikrochimica acta2024

Au@Pt@Pd nanozymes based lateral flow immunoassay for quantitative detection of SARS-CoV-2 nucleocapsid protein in nasal swab samples.

Chengcheng Li, Jinhui Lu, Chao Xiang, Enhui Zhang, Xiaofang Tian, Ling Zhang, Tingting Li, Chengyao Li

Abstract read
PubMed Publisher
In one paragraph

Article in Mikrochimica acta, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. MoSBiosensors · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chengcheng Li *Department of Transfusion Medicine, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, China.
Jinhui Lu *Department of Transfusion Medicine, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, China.
Chao Xiang *Department of Transfusion Medicine, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, China.
Enhui ZhangDepartment of Transfusion Medicine, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, China.
Xiaofang TianDepartment of Laboratory Medicine, Guangzhou University of Traditional Chinese Medicine Shenzhen Hospital, Shenzhen, 518034, China.
Ling ZhangDepartment of Transfusion Medicine, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, China. zhangling1982@163.com.
Tingting LiDepartment of Transfusion Medicine, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, China. apple-ting-007@163.com.
Chengyao LiDepartment of Transfusion Medicine, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, China. chengyaoli@hotmail.com.

Funding

China Postdoctoral Science Foundation of China 2021M691474Guangdong Natural Science Foundation Outstanding Youth Project 2022B1515020050National Natural Science Foundation of China 32070929Provincial Key Laboratory of Immune Regulation and Immunotherapy 2022B1212010009
6 · The paper itself

Abstract

Three-metal-core-shell nanoparticles (Au@Pt@PdNPs) providing excellent peroxidase-like activity were applied in lateral flow immunoassay (LFIA), designated as Au@Pt@Pd-LFIA, for detecting the nucleocapsid protein (NP) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). An Au@Pt@Pd-LFIA was developed for quantitatively testing of SARS-CoV-2 NP with a range 0.12-31.25 ng/mL. The limit of detection (LOD) of Au@Pt@Pd-LFIA strip was 0.06 ng/mL, which was 16-fold or eightfold more sensitive than that of the gold lateral flow immunoassay (Au-LFIA) and the gold flower flow immunoassay (AF-LFIA) strips, respectively. For detection of clinical samples from nasal swabs using test strips, Au@Pt@Pd-LFIA had 84.09% sensitivity, 100% specificity, and 92.55% accuracy. In terms of detection time, the testing of Au@Pt@Pd-LFIA strip was 16 min similar to Au-LFIA (15 min) and AF-LFIA (10 min), but much shorter than ELISA (2 h). In conclusion, Au@Pt@Pd-LFIA is a sensitive, rapid, and simple test for quantitative detection of SARS-CoV-2 NP in nasal swab samples.

Indexed as

Coronavirus Nucleocapsid ProteinsCOVID-19GoldLimit of DetectionMetal NanoparticlesPalladiumPlatinumSARS-CoV-2HumansImmunoassayPhosphoproteinsCoronavirus Nucleocapsid ProteinsGoldnucleocapsid phosphoprotein, SARS-CoV-2PalladiumPhosphoproteinsPlatinumAu@Pt@Pd nanozymesLateral flow immunoassaySARS-CoV-2Test stripsUltra-sensitive

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.